Ra Medical Systems Inc

Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Carlsbad, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catheter Precision, Inc. engages in the design, manufacture and sale of medical devices and technologies for cardiac electrophysiology. It offers the Amigo Remote Catheter System for accurate positioning, manipulation, and stable control of catheters for use by electrophysiologists in the diagnosis and treatment of abnormal heart rhythms. The company was founded by David Jenkins in September 2002 and is headquartered in Fort Mill, SC.

Ra Medical Systems (NYSE:RMED) releases its next round of earnings this Tuesday, May 11. Here is Benzinga's essential guide to Ra Medical Systems's Q1 earnings report.

Earnings Outlook for Ra Medical Systems

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021

Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces an increase in enrollment in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD). A total of 42 subjects have been enrolled as of April 19, 2021. “We are e

Ra Medical Systems Provides Enrollment Update for its Pivotal Atherectomy Clinical Trial

LOS ANGELES, April 14, 2021 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, announces that on March 24, 2021, the Honorable Larry Alan Burns of the United States District Court for the Southern District of California issued a ruling denying-in-part defendants' motions to dismiss in Derr v. Ra Medical Systems, Inc. GPM serves as the court-appointed Lead Counsel for a putative class of investors that purchased or otherwise acquired the securities of Ra Medical Systems, Inc. ("Ra Medical" or the "Company") (NYSE: RMED): (a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2018 initial public offering ("IPO" or the "Offering"); and/or (b) between September 27, 2018 and November 27, 2019, inclusive (the "Class Period").

Glancy Prongay & Murray LLP Obtains Important Ruling for Ra Medical Systems, Inc. Investors in Securities Fraud Class Action

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and 12 months ended December 31, 2020 and provides a business update. Recent Operational Highlights Enrolled 17 subjects in the company's atherectomy pivotal clinical trial since mid-November for a total of 30 subjects enrolled to date Completed in-house

Ra Medical Systems Reports 2020 Fourth Quarter and Full Year Financial Results

CARLSBAD, Calif.--(BUSINESS WIRE)---- $RMED #RothConference--Ra Medical Systems to participate in the Virtual 33rd Annual Roth Conference and Maxim Emerging Growth Conference in March.

Ra Medical Systems to Participate in Upcoming Virtual Investment Conferences

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report 2020 fourth quarter and full year financial results and provide a business update after market close on Tuesday, March 16, 2021. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration   Participants can pre-register for the conference call her

Ra Medical Systems to Report 2020 Fourth Quarter and Full Year Financial Results on March 16, 2021

Ra Medical Systems, Inc. (RMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Ra Medical Systems, Inc. (RMED) Report Negative Q4 Earnings? What You Should Know

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will present a company overview and hold virtual meetings with investors at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. The Ra Medical Systems presentation can be accessed by registering for the H.C. Wainwright Global Life

Ra Medical Systems to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Susanne L. Meline to its Board of Directors, effective January 31, 2021. Her appointment expands Board membership to seven. Ms. Meline has an extensive background in finance, law and corporate governance with more than 20 years of experience advising corporate clien

Ra Medical Systems Appoints Susanne L. Meline to its Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports progress with extending the shelf life of its more robust, next generation DABRA catheter, featuring a braided overjacket to improve deliverability when navigating tortuous anatomy. The Company also announces completion of all 116 items identified in a quality improvement plan that ste

Ra Medical Systems Reports Progress with Extending DABRA Catheter Shelf Life, Completes Quality Improvement Plan

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will present at the H.C. Wainwright Virtual BioConnect Conference. The Ra Medical Systems presentation can be accessed by registering for the H.C. Wainwright BioConnect Conference here. The webcast will be available beginning January 11, 2021 at 6:00 a.m. Eastern time

Ra Medical Systems to Present at H.C. Wainwright Virtual BioConnect Conference

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) today announced it has entered into a settlement agreement that resolves civil False Claims Act claims asserted by the United States Department of Justice in an investigation previously disclosed by the Company. Ra Medical Systems has settled these matters without admitting liability or wrongdoing. The allegations resolved as part of the settlement agreement reached with the U.S. Attorney's Office for the Eastern

Ra Medical Systems Announces Settlement Resolving Previously Announced United States Department of Justice and State Investigations

Caladrius Biosciences

Jianpu Technology

The short term investor may want to consider this trio of companies

A Trio of Net Net Working Capital Stocks

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems moves to the NYSE American.

Ra Medical Systems Announces Transfer of Listing to NYSE American

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announces the availability of its webcast event, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, discussing the use of excimer lasers such as the Pharos excimer laser system for the treatment of psoriasis during the pandemic. The event, featuring Theodore J. Daly, MD, FAAD, FSPD, FASD, Director of Garden City Dermatology, is available here. During the webcast, Dr. Daly reviews the American Academy of De

Ra Medical Systems Announces the Availability of its Webcast Event Discussing the Role of Excimer Lasers in the Treatment of Psoriasis During the Pandemic

LOS ANGELES, Dec. 7, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of potential claims against the board of directors of Ra Medical Systems, Inc. ("Ra Medical" or the "Company") (NYSE: RMED) concerning whether the board breached its fiduciary duties to...

The Law Offices of Frank R. Cruz Continues Its Investigation of Ra Medical Systems, Inc. (RMED) on Behalf of Investors

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) is hosting a webcast, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, featuring Theodore J. Daly, MD, FAAD, FSPD, FASD, Director of Garden City Dermatology, discussing the use of excimer lasers such as the Pharos excimer laser system for the treatment of psoriasis during the pandemic. Presentation topics will include: Reviewing American Academy of Dermatology (AAD) guidance on the use of immunosuppressi

Reminder: Ra Medical Systems to Host Webcast Discussing the Role of Excimer Lasers in the Treatment of Psoriasis during the Pandemic

In this article we will check out the progression of hedge fund sentiment towards Ra Medical Systems, Inc. (NYSE:RMED) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

Is Ra Medical Systems, Inc. (RMED) A Good Stock To Buy?

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in the Piper Sandler 32nd Annual Health Care Conference being held virtually on December 1-3, 2020. Investors interested in a 1x1 meeting with Ra Medical management during the conference should contact their Piper Sandler representative. About Ra Medical Syst

Ra Medical Systems to Participate in the Piper Sandler Virtual Health Care Conference

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will feature the Pharos excimer laser at the New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium 2020 Virtual Meeting being held November 21, 2020. “We are delighted to showcase our Pharos excimer laser at this conference,” said Will McGuire, Ra Medical Systems CEO. “Phar

Ra Medical Systems to Feature the Pharos Optimized Excimer Laser at the Virtual New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announced today that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 16, 2020. The Company's stockholders previously approved the reverse stock split at the Annual Meeting of Stockholders on November 10, 2020. The Company's shares will begin trading on a split-adjusted basis on the New York Stock Exchange

Ra Medical Systems Announces 1-for-25 Reverse Stock Split

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in A.G.P.'s Virtual Healthcare Symposium. This event, which features one-on-one meetings, is being held Thursday, November 19, 2020. Ra Medical management will be available for one-on-one meetings. Interested investors should contact Ra Medical President Jeff

Ra Medical Systems to Participate in A.G.P.'s Virtual Healthcare Symposium

Ra Medical Systems, Inc. (RMED) CEO Will McGuire on Q4 2020 Results - Earnings Call Transcript

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and nine months ended September 30, 2020 and provides a business update. Recent Operational Highlights Twelve subjects enrolled in the Company's atherectomy pivotal clinical trial, for a total of 13 subjects enrolled to date Positive test results support the path

News for Ra Medical Systems Inc Stock (RMED)